Literature DB >> 2597234

Plasma apolipoproteins in patients with multi-infarct dementia.

H Shimano1, S Ishibashi, T Murase, T Gotohda, N Yamada, F Takaku, E Ohtomo.   

Abstract

We examined 27 elderly patients with multi-infarct dementia developed on the basis of cerebral arteriosclerosis. The levels of plasma cholesterol and triglyceride in the patients were 177 +/- 48 and 91 +/- 27 mg/dl (mean +/- SD), respectively. Despite normal plasma lipid levels, the patients had significantly higher plasma apo B (102 +/- 30 vs. 82 +/- 21 mg/dl for controls, P less than 0.01) and lower plasma apo A-I levels (104 +/- 25 vs. 130 +/- 22 mg/dl for controls, P less than 0.01) than the controls. Isoelectric focusing of apo E showed a 2-fold higher relative frequency for the epsilon 4 allele in patients than in Japanese controls (20.8 vs. 8.6-11.7% of total, P less than 0.05). The patients with phenotypes of E4/4 (n = 1) and E4/3 (n = 8) had higher plasma cholesterol levels than those with E3/3 (n = 15) (196 +/- 45 vs. 169 +/- 43 mg/dl). The results indicate that the patients had abnormalities in plasma lipoprotein metabolism and this may contribute to the development of cerebral arteriosclerosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2597234     DOI: 10.1016/0021-9150(89)90132-9

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

1.  Diagnostic usefulness of apolipoprotein E epsilon 4 in the diagnosis of the dementias.

Authors:  G B Frisoni; A Bianchetti; M Trabucchi; S Govoni
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

Review 2.  Epidemiology of the dementias: recent developments and new approaches.

Authors:  C M van Duijn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-05       Impact factor: 10.154

3.  The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease.

Authors:  M Landén; A Thorsell; A Wallin; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-10       Impact factor: 10.154

4.  A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality.

Authors:  I Skoog; C Hesse; O Aevarsson; S Landahl; J Wahlström; P Fredman; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-01       Impact factor: 10.154

5.  Apolipoprotein E polymorphism in Japanese patients with Alzheimer's disease or vascular dementia.

Authors:  J Kawamata; S Tanaka; S Shimohama; K Ueda; J Kimura
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

6.  Antioxidant status and APOE genotype as susceptibility factors for neurodegeneration in Alzheimer's disease and vascular dementia.

Authors:  Giancarlo Zito; Renato Polimanti; Valentina Panetta; Mariacarla Ventriglia; Carlo Salustri; Maria Cristina Siotto; Filomena Moffa; Claudia Altamura; Fabrizio Vernieri; Domenico Lupoi; Emanuele Cassetta; Paolo M Rossini; Rosanna Squitti
Journal:  Rejuvenation Res       Date:  2013-02       Impact factor: 4.663

7.  The effect of APOE-epsilon4 on dementia is mediated by Alzheimer neuropathology.

Authors:  James A Mortimer; David A Snowdon; William R Markesbery
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Apr-Jun       Impact factor: 2.703

Review 8.  Can estrogens prevent neurodegeneration?

Authors:  L S Schneider; C E Finch
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 4.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.